Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

This phase II trial compares the effect of adding olanzapine to standard of care symptom management for nausea to standard of care alone in managing an abnormal loss of the appetite for food (anorexia) in patients treated with chemoradiation therapy (CRT) for head and neck cancer. Patients undergoing CRT may experience treatment-related side effects, including pain, nausea, and a discomfort in the ability to speak, swallow and eat. These side effects have been shown to increase weight loss, opiate use and hospitalization. Olanzapine is a drug used to treat certain mental disorders. It is also

Trial Details

NCT ID
NCT06995508
Phase
PHASE2
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Cancer Type
Squamous Cell Head and Neck Cancer
Interventions
  • Best Practice
  • Olanzapine
  • Questionnaire Administration
Locations (sample)
  • Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

  • Age ≥ 18 years old
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Diagnosed with biopsy-proven, squamous cell carcinoma of the head and neck, including squamous cell carcinoma of the neck with unknown primary site
  • Eligible for curative-intent chemoradiation therapy of the head and neck

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Head and Neck Cancer Trials on Trialify →